Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes

Core Viewpoint - Avadel Pharmaceuticals plc has successfully passed the necessary resolutions for the proposed acquisition by Alkermes plc, indicating strong shareholder support for the transaction [1][3][5]. Group 1: Scheme Meeting Results - At the Scheme Meeting, 61,861,352 shares were voted in favor of the Scheme Meeting Proposal, representing 97.41% of the votes, while 1,646,857 shares, or 2.59%, were against it [3]. - A total of 21 shareholders participated in the voting, with 20 shareholders (95.24%) voting in favor and one shareholder (4.76%) voting against the proposal [3]. - The votes in favor represented 63.03% of the total 98,151,471 Avadel shares outstanding as of the voting record time [4]. Group 2: Extraordinary General Meeting Results - At the EGM, the Scheme Approval Proposal received 62,444,065 votes in favor, accounting for 96.53%, while 2,247,706 votes (3.47%) were against it [5]. - The Articles of Association Amendment Proposal was approved with 61,808,690 votes in favor (95.85%) and 2,673,461 votes against (4.15%) [6]. - The Compensation Proposal was supported by 55,489,041 votes (86.37%), with 8,757,025 votes (13.63%) against it [6]. Group 3: Company Overview - Avadel Pharmaceuticals plc is a biopharmaceutical company focused on innovative solutions for medication development, with its commercial product LUMRYZ™ approved for treating narcolepsy [7].